In particular, upfront registration of confounding factors such as concomitant medications (inhaled and systemic corticoids), known predictive factors of ICI efficacy (tumor PD-L1 and mutational status, smoking history, immune-related toxicity), or medical conditions (parasitic infections, atopy, asthma, COPD) is of paramount importance to ascertain (a) role(s) of eosinophils in lung cancer patients treated with ICI. This evidence concerns the gene CD274 and asthma.